Situation: Phase 3 Cystic Fibrosis study

The Success: When it comes to Cystic Fibrosis studies, it is critical that CROs build and maintain strong relationships with sites.  Following study start-up for a Phase 3 Cystic Fibrosis study being conducted by Rho, the Cystic Fibrosis Foundation Therapeutics Development Network (TDN) conducted a survey of participating sites to assess their satisfaction with Rho. Some of the highlights include:

• 100% of sites ranked Rho as good or excellent for 6 of the 7 questions asked.  For the seventh question, 90% of sites ranked Rho as good or excellent.
• On all questions, Rho scored higher than the TDN average.